From protein function to cellular health
Unique approach
Most drugs inhibit proteins that contribute to disease. What if we could instead enhance proteins that can restore health?
Restore needed levels of a key protein by extending its lifespan
Relocate a misplaced protein to where it's needed in the cell
Change a protein's activity by altering its structure or interactions
Broad potential
ENTAC™ medicines enhance the function of key proteins to treat a broad range of diseases.
Target previously undruggable pathways
Address hard-to-treat genetic disorders
Treat common complex diseases
Powerful platform
Our Encompass™ platform provides an end-to-end system for efficiently creating ENTACs.
Identify targets amenable to ENTAC intervention
Validate ENTAC-disease hypothesis
Design and optimize target-specific ENTACs
Our science
ENTACs are molecular matchmakers, bringing together target proteins with enzymes called DUBs. By recruiting the right DUB for each target, ENTACs harness the natural ability of DUBs to enhance protein function.
Target protein
Critical proteins that are in short supply, are in the wrong location, or have suboptimal activity
ENTAC
Enhancement-targeting chimeras are orally available, bifunctional small molecules
Dub
Deubiquitylases selectively remove ubiquitin molecules from target proteins
Who we are
We are scientists, entrepreneurs, drug creators, and problem solvers, all inspired by the idea that even when you’re ill there’s something intact within your cells that can help you get well.
Led by executives who have successfully transformed ideas into medicines, guided by scientific founders who have helped define the DUB field, and backed by investors with the courage to push drug development’s frontiers, we’re working together to bring ENTACs to the patients who need them most.
Read more about our team
Latest news & publications
06/23/2026 Press Releases
Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors
A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced proximity therapeutics. Houston's deep experience with protein degraders will be invaluable to supporting Entact’s development of ENTAC™ medicines, which leverage the same un...
02/08/2026 Publications
Targeted recruitment of USP15 enhances CTLA4 surface levels and restricts its degradation
09/17/2024 Press Releases
Entact Bio Appoints Ruben Tommasi, Ph.D., as Chief Scientific Officer
Veteran drug developer and R&D leader with three decades of pharmaceutical and biotech experience to oversee development of targeted protein enhancement modality Watertown, MA, September 17, 2024 – Entact Bio, a company committed to improving the lives of patients by developing precision medicines that enhance the fu...
05/29/2024 Press Releases
Entact Bio Appoints Michael Gutch, Ph.D., as Chief Operating Officer
Veteran pharma and biotech executive with 20 years of operations and finance experience joins world-leading team advancing novel targeted protein enhancement modality Watertown, MA, May 29, 2024 – Entact Bio, the pioneer of precision medicines that enhance the function of beneficial proteins, today announced the appo...
Privacy & Terms of Use
Copyright © 2026